Grundlæggende statistik
| LEI | 549300OI9J7XOWZMUN85 |
| CIK | 1932393 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GE HealthCare Technologies Inc
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 (State or other jurisdiction of incorporation) (Commission File Number) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) Frank Jimenez (833) |
|
| May 29, 2026 |
GE HEALTHCARE TECHNOLOGIES INC. Conflict Minerals Report Year ended December 31, 2025 Exhibit 1.01 GE HEALTHCARE TECHNOLOGIES INC. Conflict Minerals Report Year ended December 31, 2025 1.Introduction GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our” or “we”) has prepared this Conflict Minerals Report (the “Report”) for the calendar year ended December 31, 2025, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). Terms used and not |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2026 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commiss |
|
| April 29, 2026 |
GE HealthCare reports first quarter 2026 financial results Exhibit 99 GE HealthCare reports first quarter 2026 financial results •Revenue growth of 7. |
|
| April 29, 2026 |
Exhibit 10.2 Execution Version AMENDMENT NO. 1 AMENDMENT NO. 1, dated as of February 26, 2026 (this “Amendment”), among GE Healthcare Technologies Inc. (the “Borrower”), each Lender (as defined in the Credit Agreement (as defined below)) and JPMorgan Chase Bank, N.A., as Administrative Agent (as defined in the Credit Agreement). WITNESSETH: WHEREAS, reference is made to that certain Credit Agreeme |
|
| April 29, 2026 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2026 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| April 29, 2026 |
Exhibit 10.7 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare New Hire Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Percentage of RSUs Vesting Date <> <> 33% <> 33% <> 34% <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of the Board o |
|
| April 29, 2026 |
GE HealthCare Stock Option Grant Agreement (“Grant Agreement”) For <<Employee Name>> (“Grantee”) Exhibit 10.5 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Percentage of Option Shares Vesting Date <> <> $ <> 1, <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> *Exercise p |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHC |
|
| April 29, 2026 |
Exhibit 10.4 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Percentage of RSUs Vesting Date <> <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of th |
|
| April 29, 2026 |
Exhibit 10.8 Global Addendum Global Information for the GE HealthCare Technologies Inc. (“GE HealthCare” or “Company”) 2023 Long-Term Incentive Plan (the “Plan”) January 2026 This Addendum provides additional terms and conditions of your grant in Section A and specific additional terms and conditions and/or notifications that apply to participants who reside, are employed and/or otherwise subject |
|
| April 29, 2026 |
Exhibit 10.6 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Performance Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date PSUs Granted Vesting Schedule Percentage of PSUs1 Vesting Date <> 100% The date in Q1 2029 on which the Committee (as defined below) certifies PSU performance 1Actual number of shares |
|
| March 19, 2026 |
a2026proxynotice Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 19, 2026 |
2025 Annual ReportLetter from the CEO Dear Fellow GE HealthCare Stockholders, 2025 was a year of disciplined execution and operational resilience as our industry continued to navigate a dynamic global environment, including tariffs. |
|
| March 19, 2026 |
Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. |
|
| March 17, 2026 |
GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors CHICAGO —(BUSINESS WIRE)— March 17, 2026— GE HealthCare (Nasdaq: GEHC) announced today the appointment of Kevin A. |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 13, 2026 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 26, 2026 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| February 27, 2026 |
Exhibit 10.1 Execution Version 364-DAY REVOLVING CREDIT AGREEMENT dated as of February 26, 2026 among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, JPMORGAN CHASE BANK, N.A., as the Administrative Agent, and The Lenders Party Hereto $500,000,000 REVOLVING CREDIT FACILITY JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and M |
|
| February 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation o |
|
| February 4, 2026 |
Exhibit 21.1 GE HealthCare Technologies Inc. Subsidiaries of Registrant As of December 31, 2025 LEGAL ENTITY STATE OR COUNTRY OF INCORPORATION OR ORGANIZATION Beijing GE Hualun Medical Equipment Company Limited China BK Medical ApS Denmark BK Medical Australia Pty Ltd. Australia BK Medical Holding Company, Inc. Delaware BK Medical Technology Shanghai Co., Ltd. China BKM Holding Company, Inc. Delaw |
|
| February 4, 2026 |
GE HEALTHCARE TECHNOLOGIES INC. SECURITIES TRADING POLICY Amended as of June 24, 2025 Exhibit 19.1 GE HEALTHCARE TECHNOLOGIES INC. SECURITIES TRADING POLICY Amended as of June 24, 2025 I.Purpose To describe the standards concerning the handling of non-public information relating to GE HealthCare Technologies Inc. and its subsidiaries (the “Company”) and the buying, selling, and other trading of securities of the Company. II.Persons Affected and Prohibited Transactions This Policy a |
|
| February 4, 2026 |
Exhibit 99 GE HealthCare reports fourth quarter and full year 2025 financial results Company exceeds topline and earnings per share expectations; demonstrates operational resilience Fourth quarter 2025 highlights(1) •Revenue growth of 7. |
|
| February 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2026 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| December 15, 2025 |
EX-10.1 Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of December 12, 2025 among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, JPMORGAN CHASE BANK, N.A, as the Administrative Agent, and The Lenders Party Hereto $750,000,000 TERM LOAN CREDIT FACILITY GOLDMAN SACHS BANK USA, BNP PARIBAS SECURITIES CORP., JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC., CITIBANK, N.A. and MORGAN STANL |
|
| December 15, 2025 |
EX-4.2 Exhibit 4.2 GE HEALTHCARE TECHNOLOGIES INC. and THE BANK OF NEW YORK MELLON, as Trustee FOURTH SUPPLEMENTAL INDENTURE Dated as of December 15, 2025 to INDENTURE Dated as of November 22, 2022 Relating to $600,000,000 of 4.150% Senior Notes due 2028 $650,000,000 of 4.950% Senior Notes due 2035 TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION Section 1 |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 12, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| December 2, 2025 |
EX-1.1 Exhibit 1.1 Execution Version GE HealthCare Technologies Inc. 4.150% Senior Notes due 2028 4.950% Senior Notes due 2035 Underwriting Agreement December 1, 2025 Goldman Sachs & Co. LLC BNP Paribas Securities Corp. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o BNP Pa |
|
| December 2, 2025 |
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 Prospectus Supplement to Prospectus dated June 28, 2024 $1,250,000,000 GE HealthCare Technologies Inc. $600,000,000 4.150% Senior Notes due 2028 $650,000,000 4.950% Senior Notes due 2035 We are offering $600,000,000 aggregate principal amount of 4.150% senior notes due 2028 (the “2028 notes”), and $650,000,000 agg |
|
| December 2, 2025 |
Calculation of Filing Fee Tables S-3 GE HealthCare Technologies Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry For |
|
| December 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 1, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| December 1, 2025 |
SUBJECT TO COMPLETION, DATED DECEMBER 1, 2025 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is |
|
| December 1, 2025 |
FWP Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated December 1, 2025 To Prospectus dated June 28, 2024 Registration File No. |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEA |
|
| October 29, 2025 |
GE HealthCare reports third quarter 2025 financial results Exhibit 99 GE HealthCare reports third quarter 2025 financial results •Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U. |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 29, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| September 22, 2025 |
144 0001889865 XXXXXXXX LIVE 0001932393 GE HealthCare Technologies Inc. 001-41528 500 W. Monroe Street Chicago IL 60661 8337351139 Kenneth Stacherski Former Officer Common Shares UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086 19524 1453773 456562037 09/22/2025 NASDAQ Common 09/01/2024 Restricted Stock Vest GE HealthCare Technologies Inc. N 1185 09/22/2025 NA Common 11/01/ |
|
| September 12, 2025 |
144 0001889865 XXXXXXXX LIVE 0001932393 GE HealthCare Technologies Inc. 001-41528 500 W. Monroe Street Chicago IL 60661 8337351139 Kenneth Stacherski Former Officer Common Shares UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086 11757 905590 456562037 09/12/2025 NASDAQ Common 09/12/2025 Stock Option Exercise GE HealthCare Technologies Inc. N 11757 09/12/2025 NA Y 09/12/2025 |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHCA |
|
| July 30, 2025 |
GE HealthCare reports second quarter 2025 financial results Exhibit 99 GE HealthCare reports second quarter 2025 financial results •Revenue growth was 3% year-over-year; Organic revenue growth* was 2% •Net income margin was 9. |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis |
|
| June 9, 2025 |
Exhibit 4.2 GE HEALTHCARE TECHNOLOGIES INC. and THE BANK OF NEW YORK MELLON, as Trustee THIRD SUPPLEMENTAL INDENTURE Dated as of June 9, 2025 to INDENTURE Dated as of November 22, 2022 Relating to $650,000,000 of 4.800% Notes due 2031 $850,000,000 of 5.500% Notes due 2035 i ii THIRD SUPPLEMENTAL INDENTURE THIRD SUPPLEMENTAL INDENTURE, dated as of June 9, 2025 (this “Third Supplemental Indenture”), |
|
| June 5, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 GE HealthCare Technologies Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Eff |
|
| June 5, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 Prospectus Supplement to Prospectus dated June 28, 2024 $1,500,000,000 GE HealthCare Technologies Inc. $650,000,000 4.800% Senior Notes due 2031 $850,000,000 5.500% Senior Notes due 2035 We are offering $650,000,000 aggregate principal amount of 4.800% senior notes due 2031 (the “2031 notes”), and $850,000,000 aggregate |
|
| June 4, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis |
|
| June 4, 2025 |
, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC, as representatives of the se Execution Version GE HealthCare Technologies Inc. 4.800% Senior Notes due 2031 5.500% Senior Notes due 2035 Underwriting Agreement June 3, 2025 Citigroup Global Markets Inc. J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 1 |
|
| June 3, 2025 |
SUBJECT TO COMPLETION, DATED JUNE 3, 2025 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is |
|
| June 3, 2025 |
FWP Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated June 3, 2025 To Prospectus dated June 28, 2024 Registration File No. |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis |
|
| May 29, 2025 |
GE HealthCare 2024 Conflict Minerals Report Exhibit 1.01 GE HEALTHCARE TECHNOLOGIES INC. Conflict Minerals Report Year ended December 31, 2024 1.Introduction GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our” or “we”) has prepared this Conflict Minerals Report (the “Report”) for the calendar year ended December 31, 2024, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). Terms used and not |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 (State or other jurisdiction of incorporation) (Commission File Number) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) Frank Jimenez (833) |
|
| April 30, 2025 |
Exhibit 10.8 Global Addendum Global Information for the GE HealthCare Technologies Inc. (“GE HealthCare” or “Company”) 2023 Long-Term Incentive Plan (the “Plan”) January 2025 This Addendum provides additional terms and conditions of your grant in Section A and specific additional terms and conditions and/or notifications that apply to participants who reside, are employed and/or otherwise subject |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHC |
|
| April 30, 2025 |
Exhibit 10.4 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of the Bo |
|
| April 30, 2025 |
althCare New Hire Restricted Stock Unit Grant Agreement. Exhibit 10.7 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare New Hire Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% <> 33% <> 34% <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of the Board of Di |
|
| April 30, 2025 |
with Roland Rott, dated as of June Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIV |
|
| April 30, 2025 |
2025 GE HealthCare Performance Stock Unit Exhibit 10.6 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Performance Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date PSUs Granted Vesting Schedule Number of PSUs1 Vesting Date <> <> 100% The date in Q1 of <> on which the Committee (as defined below) certifies PSU performance 1Actual number of shares |
|
| April 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| April 30, 2025 |
GE HealthCare reports first quarter 2025 financial results Exhibit 99 GE HealthCare reports first quarter 2025 financial results •Revenue growth was 3% year-over-year; Organic revenue growth* was 4% •Net income margin was 11. |
|
| April 30, 2025 |
Exhibit 10.5 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date <> <> $ <> 1, <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> *Exercise price |
|
| April 10, 2025 |
2024 Annual ReportLetter from the CEO Dear Fellow GE HealthCare Stockholders, As we reflect on 2024, I’m proud to share the progress we’ve made in executing our precision care strategy since becoming an independent company. |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| April 10, 2025 |
gehealthcarenotice2025 Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. |
|
| March 31, 2025 |
Exhibit 10.2 Execution Version 364-DAY REVOLVING CREDIT AGREEMENT dated as of March 27, 2025 among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, JPMORGAN CHASE BANK, N.A., as the Administrative Agent, and The Lenders Party Hereto $500,000,000 REVOLVING CREDIT FACILITY JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORG |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| March 31, 2025 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of March 27, 2025 among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, JPMORGAN CHASE BANK, N.A., as the Administrative Agent, and The Lenders Party Hereto $3,000,000,000 REVOLVING CREDIT FACILITY JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIO |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation o |
|
| February 13, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 GE HealthCare Technologies Inc. Subsidiaries of Registrant As of December 31, 2024 LEGAL ENTITY STATE OR COUNTRY OF INCORPORATION OR ORGANIZATION Beijing GE Hualun Medical Equipment Company Limited China BK Medical ApS Denmark BK Medical Australia Pty Ltd. Australia BK Medical Austria GmbH Austria BK Medical France SAS France BK Medical Holding Company, Inc. Delaware BK Medical Italia |
|
| February 13, 2025 |
ealthCare Technologies Inc. Securities Trading Policy. Exhibit 19.1 GE HEALTHCARE TECHNOLOGIES INC. SECURITIES TRADING POLICY Amended as of January 14, 2025 I.Purpose To describe the standards concerning the handling of non-public information relating to GE HealthCare Technologies Inc. and its subsidiaries (the “Company”) and the buying, selling, and other trading of securities of the Company. II.Persons Affected and Prohibited Transactions This Polic |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| February 13, 2025 |
GE HealthCare reports fourth quarter and full year 2024 financial results Exhibit 99 GE HealthCare reports fourth quarter and full year 2024 financial results Fourth Quarter 2024 •Revenue growth was 2% year-over-year; Organic revenue growth* was 2% •Net income margin was 13. |
|
| December 12, 2024 |
Exhibit 10.1 Execution Version 364-DAY REVOLVING CREDIT AGREEMENT dated as of December 11, 2024 Among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, CITIBANK, N.A., as the Administrative Agent, And The Lenders Party Hereto $1,000,000,000 REVOLVING DOLLAR AND EURO CREDIT FACILITY CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIOR |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| November 21, 2024 |
Exhibit 99 GE HealthCare hosts 2024 Investor Day: focus on innovation to deliver precision care and drive growth Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% CHICAGO — November 21, 2024 — GE HealthCare (Nasdaq: GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* GE HealthCare Technologies Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36266G107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 8, 2024 |
13,281,302 shares GE HealthCare Technologies Inc. Common Stock Filed pursuant to Rule 424(b)(3) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 13,281,302 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 13,281,302 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and the accompanying prospe |
|
| November 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) GE HealthCare Technologies Inc. |
|
| November 8, 2024 |
Exhibit 1.1 13,281,302 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT November 7, 2024 November 7, 2024 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Morgan S |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| November 8, 2024 |
GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares November 7, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not sell |
|
| November 8, 2024 |
GEHC / GE HealthCare Technologies Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us36266g1076110824.txt us36266g1076110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) GE HealthCare Technologies Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 36266G107 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 7, 2024 |
GE HealthCare Technologies Inc. Commences Secondary Offering of 13,281,302 Shares Free Writing Prospectus dated November 7, 2024 Filed Pursuant to Rule 433 Registration Statement No. |
|
| October 30, 2024 |
GE HealthCare reports third quarter 2024 financial results Exhibit 99 GE HealthCare reports third quarter 2024 financial results •Revenue growth was 1% year-over-year; Organic revenue growth* was 1% •Net income margin was 9. |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEA |
|
| October 30, 2024 |
Exhibit 99 GE HealthCare Recast Unaudited Historical Financial Information Reflecting the Company’s New Reportable Segment Structure Effective July 1, 2024, Image Guided Therapies (“IGT”), previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| October 22, 2024 |
GEHC / GE HealthCare Technologies Inc. / GENERAL ELECTRIC CO - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 eh24053401413ga3-gehc.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* GE HEALTHCARE TECHNOLOGIES INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 36266G 107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta |
|
| October 22, 2024 |
GEHC / GE HealthCare Technologies Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us36266g1076102224.txt us36266g1076102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) GE HealthCare Technologies Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 36266G107 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the a |
|
| September 13, 2024 |
GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 15,000,000 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 15,000,000 Shares September 12, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 15,000,000 shares of its common stock (the “GEHC Shares”) at a public offe |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) ( |
|
| September 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) GE HealthCare Technologies Inc. |
|
| September 13, 2024 |
15,000,000 shares GE HealthCare Technologies Inc. Common Stock Filed pursuant to Rule 424(b)(3) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 15,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 15,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and the accompanying prospe |
|
| September 13, 2024 |
Exhibit 1.1 Execution Version 15,000,000 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT September 12, 2024 September 12, 2024 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stoc |
|
| September 12, 2024 |
GE HealthCare Technologies Inc. Commences Secondary Offering of 10,000,000 Shares Free Writing Prospectus dated September 12, 2024 Filed Pursuant to Rule 433 Registration Statement No. |
|
| August 15, 2024 |
8-K filed with the SEC on August 15, 2024). Exhibit 4.2 GE HEALTHCARE TECHNOLOGIES INC. and THE BANK OF NEW YORK MELLON, as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of August 14, 2024 to INDENTURE Dated as of November 22, 2022 Relating to $1,000,000,000 of 4.800% Notes due 2029 TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION Section 1.01 References 1 Section 1.02 Definitions 2 ARTICLE TWO GEN |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424 (b)(2) (Form Type) GE HealthCare Technologies Inc. |
|
| August 9, 2024 |
Exhibit 1.1 GE HealthCare Technologies Inc. 4.800% Senior Notes due 2029 Underwriting Agreement August 7, 2024 Goldman Sachs & Co. LLC BofA Securities, Inc. Morgan Stanley & Co. LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 c/o BofA Securities, Inc. One Bryant Park Ne |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2024 |
GE HealthCare Technologies Inc. $1,000,000,000 4.800% Senior Notes due 2029 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 Prospectus Supplement to Prospectus dated June 28, 2024 GE HealthCare Technologies Inc. $1,000,000,000 4.800% Senior Notes due 2029 We are offering $1,000,000,000 aggregate principal amount of 4.800% senior notes due 2029 (the “notes”). Interest on the notes will be payable in cash semi-annually in arrears on February 1 |
|
| August 7, 2024 |
FWP 1 d848981dfwp.htm FWP Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated August 7, 2024 To Prospectus dated June 28, 2024 Registration File No. 333-280584 GE HealthCare Technologies Inc. August 7, 2024 $1,000,000,000 4.800% Senior Notes due 2029 PRICING TERM SHEET Issuer: GE HealthCare Technologies Inc. (the “Issuer”) Trade Date: August 7, 2024 Settlement Date: Augu |
|
| August 7, 2024 |
SUBJECT TO COMPLETION, DATED AUGUST 7, 2024 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is |
|
| July 31, 2024 |
GE HealthCare reports second quarter 2024 financial results Exhibit 99 GE HealthCare reports second quarter 2024 financial results •Revenues were flat year-over-year; Organic revenue growth* was 1% •Net income margin was 8. |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHCA |
|
| June 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) GE HealthCare Technologies Inc. |
|
| June 28, 2024 |
Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju |
|
| June 28, 2024 |
As filed with the U.S. Securities and Exchange Commission on June 28, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on June 28, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or Other Jurisdiction of Incor |
|
| May 30, 2024 |
Exhibit 1.01 GE HEALTHCARE TECHNOLOGIES INC. Conflict Minerals Report Year ended December 31, 2023 1.Introduction GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our” or “we”) has prepared this Conflict Minerals Report (the “Report”) for the calendar year ended December 31, 2023, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). Terms used and not |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 (State or other jurisdiction of incorporation) (Commission File Number) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) Frank Jimenez (833) |
|
| May 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis |
|
| April 30, 2024 |
024 GE HealthCare Restricted Stock Unit Agreement ( Exhibit 10.1 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of the Bo |
|
| April 30, 2024 |
GE HealthCare Reports First Quarter 2024 Financial Results Exhibit 99 GE HealthCare Reports First Quarter 2024 Financial Results •Revenues declined 1% year-over-year; Organic revenue growth* was approximately flat •Net income margin was 8. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| April 30, 2024 |
E HealthCare Performance Stock Unit Grant Exhibit 10.3 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Performance Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date PSUs Granted Vesting Schedule Number of PSUs1 Vesting Date <> <> 100% The date in Q1 <> on which the Committee (as defined below) certifies PSU performance 1Actual number of shares of |
|
| April 30, 2024 |
are Stock Option Grant Agreement (incorporated by reference to Exhibit 10.2 to the Registrant Exhibit 10.2 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date <> <> $ <> 1, <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> *Exercise price |
|
| April 30, 2024 |
d by reference to Exhibit 10.5 to the Registrant Exhibit 10.5 Peter J. Arduini President and Chief Executive Officer GE Healthcare 500 West Monroe Street Chicago, IL 60661 9th September 2022 Mr Taha Kass-Hout Dear Taha We are pleased to offer you the position of Chief Science & Clinical Technology Officer (final title to be agreed to) for GE Healthcare. The details of this offer, which is contingent upon the successful completion of a background |
|
| April 30, 2024 |
Exhibit 10.4 Global Addendum Global Information for the GE HealthCare Technologies Inc. (“GE HealthCare” or “Company”) 2023 Long-Term Incentive Plan (the “Plan”) January 2024 This Addendum provides additional terms and conditions of your grant in Section A and specific additional terms and conditions and/or notifications that apply to participants who reside and/or are employed in one of the count |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHC |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2024 |
Annual Report 2023 Board of Directors About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patien |
|
| April 4, 2024 | ||
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| April 2, 2024 |
GEHC / GE HealthCare Technologies Inc. / GENERAL ELECTRIC CO - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 eh24045986913ga2-gehc.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* GE HEALTHCARE TECHNOLOGIES INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 36266G 107 (CUSIP Number) March 31, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| March 14, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) GE HealthCare Technologies Inc. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 12, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| March 14, 2024 |
GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares March 12, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 14,000,000 shares of its common stock (the “GEHC Shares”). The Offering was up |
|
| March 14, 2024 |
Exhibit 1.1 Execution Version 14,000,000 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT March 12, 2024 March 12, 2024 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stockholder (in such capacity, the “Selling Stockholder”) of the stock of GE HealthCare |
|
| March 14, 2024 |
14,000,000 shares GE HealthCare Technologies Inc. Common Stock 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 14,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 14,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and |
|
| March 12, 2024 |
GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares Free Writing Prospectus dated March 12, 2024 Filed Pursuant to Rule 433 Registration Statement No. |
|
| March 11, 2024 |
GEHC / GE HealthCare Technologies Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: GE HealthCare Technologies Inc Title of Class of Securities: Common Stock CUSIP Number: 36266G107 Date of Event Which Requires Filing of this Statement: February 29, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 16, 2024 |
GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares Exhibit 99.2 GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares February 16, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering pric |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 15, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| February 16, 2024 |
13,000,000 shares GE HealthCare Technologies Inc. Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 13,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 13,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and the a |
|
| February 16, 2024 |
GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares February 15, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of co |
|
| February 16, 2024 |
Exhibit 1.1 13,000,000 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT February 15, 2024 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stockholder (in such capacity, the “Selling Stockholder |
|
| February 15, 2024 |
As filed with the U.S. Securities and Exchange Commission on February 15, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on February 15, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or Other Jurisdiction of Inco |
|
| February 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) GE HealthCare Technologies Inc. |
|
| February 15, 2024 |
Subject to Completion Preliminary Prospectus Supplement dated February 15, 2024 Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-277108 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not per |
|
| February 13, 2024 |
SC 13G 1 tv0999-gehealthcaretechnolog.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: GE HealthCare Technologies Inc Title of Class of Securities: Common Stock CUSIP Number: 36266G107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the ru |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* GE HealthCare Technologies Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36266G107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 9, 2024 |
As filed with the U.S. Securities and Exchange Commission on February 9, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on February 9, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or Other Jurisdiction of I |
|
| February 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) GE HealthCare Technologies Inc. |
|
| February 6, 2024 |
Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Fourth Quarter 2023 •Revenue growth was 5% year-over-year; Organic revenue growth* of 5% •Net income margin was 7. |
|
| February 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) ( |
|
| February 6, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 GE HealthCare Technologies Inc. Subsidiaries of Registrant LEGAL ENTITY STATE OR COUNTRY OF INCORPORATION OR ORGANIZATION Beijing GE Hualun Medical Equipment Company Limited China BK Medical ApS Denmark BK Medical Australia Pty Ltd. Australia BK Medical Austria GmbH Austria BK Medical Benelux NV Belgium BK Medical France SAS France BK Medical Holding Company, Inc. United States BK Med |
|
| February 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| February 6, 2024 |
Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Fourth Quarter 2023 •Revenue growth was 5% year-over-year; Organic revenue growth* of 5% •Net income margin was 7. |
|
| February 6, 2024 |
GE HealthCare Technologies Inc. Clawback Policy Exhibit 97.1 GE HEALTHCARE TECHNOLOGIES INC. CLAWBACK POLICY The Board of Directors (“Board”) of GE HealthCare Technologies Inc. (“Company”) has adopted this Clawback Policy (“Policy”) effective as of October 2, 2023, (i) in part to comply with, and it shall be interpreted consistent with, Section 10D of the Securities Exchange Act of 1934, as amended (“Exchange Act”), Rule 10D-1 promulgated under |
|
| February 6, 2024 |
Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Fourth Quarter 2023 •Revenue growth was 5% year-over-year; Organic revenue growth* of 5% •Net income margin was 7. |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation o |
|
| February 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) ( |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 29, 2024 |
US36266G1076 / GE HealthCare Technologies, Inc. / BlackRock Inc. Passive Investment SC 13G 1 us36266g1076012924.txt us36266g1076012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) GE HealthCare Technologies Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 36266G107 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 13, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| December 15, 2023 |
364-Day Revolving Credit Agreement, dated as of Exhibit 10.1 Execution Version 364-DAY REVOLVING CREDIT AGREEMENT dated as of December 13, 2023 Among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, CITIBANK, N.A., as the Administrative Agent, And The Lenders Party Hereto $1,000,000,000 REVOLVING DOLLAR AND EURO CREDIT FACILITY CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIOR |
|
| October 31, 2023 |
s Quarterly Report on Form 10-Q filed with the SEC on October 31, 2023). Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS SEPARATION AGREEMENT & RELEASE HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. SUCH CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGIST |
|
| October 31, 2023 |
GE HealthCare Reports Third Quarter 2023 Financial Results Exhibit 99 GE HealthCare Reports Third Quarter 2023 Financial Results •Revenue growth was 5% year-over-year; Organic revenue growth* of 6% •Net income attributable to GE HealthCare was $375 million versus $487 million for the prior year; Adjusted EBIT* $744 million versus $700 million •Net income margin was 7. |
|
| October 31, 2023 |
GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 5 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEA |
|
| October 31, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| October 31, 2023 |
GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-272419 Prospectus Supplement No. 2 to Prospectus Dated June 7, 2023 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated June 7, 2023 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) by the selling stockho |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2023 |
GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 4 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be |
|
| July 25, 2023 |
Power of Attorney (contained on signature page hereto). POS AM Table of Contents As filed with the U.S. Securities and Exchange Commission on July 25, 2023. Registration No. 333-268797 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 3844 88-25 |
|
| July 25, 2023 |
GE HealthCare Reports Second Quarter 2023 Financial Results Exhibit 99 GE HealthCare Reports Second Quarter 2023 Financial Results •2Q Revenue growth of 7% year-over-year; Organic revenue growth* of 9% •2Q Net income attributable to GE HealthCare of $418 million versus $485 million for the prior year, Adjusted EBIT* of $711 million versus $719 million •2Q Diluted EPS was $0. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHCA |
|
| July 25, 2023 |
Exhibit 10.2 [Logo] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS OFFER LETTER HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TRE |
|
| July 25, 2023 |
GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-272419 Prospectus Supplement No. 1 to Prospectus Dated June 7, 2023 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated June 7, 2023 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) by the selling stockho |
|
| July 25, 2023 |
Exhibit 10.1 GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team Section I.Purpose and Effective Date The GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (the “Plan”) provides severance benefits under specified conditions to the CEO and Executives who experience a Qualifying Termination on or after April 1, 2023 (the “Effective Date”) |
|
| June 8, 2023 |
25,000,000 shares GE HealthCare Technologies Inc. Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-272419 PROSPECTUS SUPPLEMENT (To Prospectus dated June 7, 2023) 25,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 25,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement |
|
| June 5, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 5, 2023. S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 5, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 3844 88-2515116 (State or Other Jurisdiction of |
|
| June 5, 2023 |
Form of Underwriting Agreement. Exhibit 1.1 [●] Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT [●], 2023 [●], 2023 Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stockholder (in such capacity, the “Selling Stockholder” |
|
| June 5, 2023 |
CORRESP June 5, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, DC 20549-6010 Attention: Jessica Ansart Re: GE HealthCare Technologies Inc. Registration Statement on Form S-1 (File No. 333-272419) Dear Ms. Ansart: In accordance with Rule 461 under the Securities Act of 1933, as amen |
|
| June 5, 2023 |
GE HealthCare Technologies Inc. 500 W. Monroe Street Chicago, Illinois 60661 GE HealthCare Technologies Inc. 500 W. Monroe Street Chicago, Illinois 60661 June 5, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, DC 20549-6010 Attention: Jessica Ansart Re: GE HealthCare Technologies Inc. Registration Statement on Form S-1 (File No. 333-272419) Dear Ms. Ansart: |
|
| June 5, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GE HealthCare Technologies Inc. |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 500 W. Monroe Street Chicago, IL 60661 (Address of principal execut |
|
| May 31, 2023 |
Exhibit 1.01 General Electric Company 2022 Conflict Minerals Report Introduction General Electric Company (“GE” or the “Company”) has prepared this Conflict Minerals Report (“Report”) for the year ended December 31, 2022, as provided for in Rule 13p-1 of the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Conflict Minerals Rule”). GE manufactures a wide range of produc |
|
| May 25, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GE HealthCare Technologies Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36266G107 (CUSIP Number) April 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of Registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| May 9, 2023 |
GE HealthCare Names James Saccaro Vice President and Chief Financial Officer Exhibit 99 GE HealthCare Names James Saccaro Vice President and Chief Financial Officer Chicago, IL – May 9, 2023 – GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, has named James "Jay” Saccaro as vice president and chief financial officer (CFO), succeeding Helmut Zodl who is remaining with the Company to lead special projects regarding separation from GE. |
|
| May 4, 2023 |
GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, IL 60661 CORRESP GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, IL 60661 May 4, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park and Abby Adams Re: GE HealthCare Technologies Inc. Registration Statement on Form S-4 (File No. 333-271435) Dear Ms. Park and Ms. Adams: In accordance with Rule 461 of t |
|
| May 2, 2023 |
United States securities and exchange commission logo May 2, 2023 Peter Arduini Chief Executive Officer and Director GE HealthCare Technologies Inc. |
|
| April 25, 2023 |
Exhibit 10.10 [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> Grant Date RSUs Granted Vesting Date Date <> the earlier of the date of the Company’s next annual stockholder meeting or the one-year anniversary of the Grant Date 1. Grant. The Board of Directors of |
|
| April 25, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) GE HealthCare Technologies Inc. |
|
| April 25, 2023 |
Exhibit 10.15 EMPLOYMENT CONTRACT Between: GE Healthcare Limited (“the Company”) And: Jan Makela (“you”) YOUR KEY TERMS Job Title Base Salary President & CEO, Healthcare Imaging reporting to Peter Arduini, President & CEO, GE Healthcare £530,000 per year payable monthly on or about the 15th. This is also known as your Reference Pay. Incentive Plan Continuing membership of the One GE HealthCare Ann |
|
| April 25, 2023 |
0 (incorporated by reference to Exhibit 10 Exhibit 10.12 Katya Kruglova Vice President, Human Resources GE Healthcare Improving Lives in the Moments that Matter November 25th, 2020 Helmut Zodl Dear Helmut, We are pleased to offer you the position of Vice President-Chief Financial Officer, in GE Healthcare (the “business,” within General Electric Company, the “company”) on a mutual agreed start date (your “start date”). This position will b |
|
| April 25, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on April 25, 2023 Registration No. |
|
| April 25, 2023 |
Exhibit 10.11 [Logo] [Date] Equity Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“LTIP”) GE HealthCare Deferred Stock Unit Agreement (“Agreement”) For <> Grant Date Deferred Stock Units (“DSUs”) Date <> 1. Grant. The individual named in this Agreement (“Recipient”) elected to defer cash retainers otherwise payable for service on the Board of Directors of GE HealthCare Te |
|
| April 25, 2023 |
GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, Illinois 60661 CORRESP GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, Illinois 60661 April 25, 2023 BY EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 GE HealthCare Technologies Inc. Registration Statement on Form S-4 Ladies and Gentlemen: GE HealthCare Technologies Inc. (the “Company”) has filed a registration statement on Form S- |
|
| April 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| April 25, 2023 |
Exhibit 10.9 Non-Employee Director Compensation and Benefits Plan Compensation Element Amount Board Cash* $125,000 Board Equity Restricted Stock Units (RSUs)* $200,000 Committee Chair Cash Retainer* Audit $ 25,000 Compensation $ 20,000 Nominating & Governance $ 15,000 Board Leadership Cash Retainer* Lead Independent Director $ 40,000 Non-Executive Chair $130,000 Stock Ownership Requirements 5x Boa |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHC |
|
| April 25, 2023 |
Exhibit 10.13 GE Healthcare Peter J. Arduini President and Chief Executive Officer 500 West Monroe Street Chicago, IL 60661 February 4, 2022 Mr. Frank Jimenez Dear Frank: We are pleased to offer you the position of Group Vice President & General Counsel for GE Healthcare. The details of this offer, which is contingent upon the successful completion of a background check, reference check, and a dru |
|
| April 25, 2023 |
CORRESP Paul, Weiss, Rifkind, Wharton & Garrison LLP 1285 Avenue of the Americas New York, New York 10019-6064 April 25, 2023 Via EDGAR Securities and Exchange Commission 100 F Street, N. |
|
| April 25, 2023 |
GE HealthCare Reports First Quarter 2023 Financial Results Exhibit 99 GE HealthCare Reports First Quarter 2023 Financial Results •1Q Revenue growth of 8% year-over-year; Organic revenue* growth of 12% •1Q Net income attributable to GE HealthCare of $372 million versus $389 million for the prior year, Adjusted EBIT* of $664 million versus $599 million •1Q Diluted EPS was $0. |
|
| April 25, 2023 |
EX-99.1 Exhibit 99.1 LETTER OF TRANSMITTAL To Tender for Exchange $1,000,000,000 aggregate principal amount 5.550% Senior Notes due 2024 (CUSIP Numbers 36267VAA1 / U3644QAA3) $1,500,000,000 aggregate principal amount 5.600% Senior Notes due 2025 (CUSIP Numbers 36267VAC7 / U3644QAB1) $1,750,000,000 aggregate principal amount 5.650% Senior Notes due 2027 (CUSIP Numbers 36267VAE3 / U3644QAC9) $1,250, |
|
| April 25, 2023 |
GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 3 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be |
|
| April 25, 2023 |
EX-25 Exhibit 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☒ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 |
|
| April 25, 2023 |
Offer Letter with Betty D. Larson, dated January 21, 2022. Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS OFFER LETTER HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS |
|
| April 20, 2023 |
United States securities and exchange commission logo April 20, 2023 Peter Arduini Chief Executive Officer and Director GE HealthCare Technologies Inc. |
|
| April 18, 2023 |
Table of Contents Confidential Treatment Requested by GE HealthCare Technologies Inc. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 5, 2023 |
Annual Report 2022 gehealthcare.comBoard of Directors About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| April 5, 2023 |
GE HealthCare Technologies Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-268797 Prospectus Supplement No. 2 (to Prospectus dated December 14, 2022) GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) th |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm |
|
| March 24, 2023 |
Exhibit 10.1 GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team Section I.Purpose and Effective Date The GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (the “Plan”) provides severance benefits under specified conditions to the CEO and Executives who experience a Qualifying Termination on or after April 1, 2023 (the “Effective Date”) |
|
| March 3, 2023 |
Exhibit 10.2 FORM OF AWARD FOR SECTION 16 OFFICERS [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare [Year] Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date <> <> $ [Month] 1, |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi |
|
| March 3, 2023 |
Exhibit 10.1 FORM OF AWARD FOR SECTION 16 OFFICERS OF COMPANY [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Technologies [Year] Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% [Month] 1, [Year] 33% [Month] 1, [Year] |
|
| March 3, 2023 |
Exhibit 10.3 FORM OF AWARD FOR SECTION 16 OFFICERS OF COMPANY [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare [Year] Performance Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date PSUs Granted Vesting Schedule Number of PSUs1 Vesting Date <> <> 100% The date in Q1 [Year] on which the Committee (as d |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C |
|
| February 15, 2023 |
United States Securities and Exchange Commission WASHINGTON, D.C. 20549 FORM 10-K ☑ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation o |
|
| February 15, 2023 |
GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 1 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be |
|
| February 15, 2023 |
As filed with the Securities and Exchange Commission on February 15, 2023 As filed with the Securities and Exchange Commission on February 15, 2023 Registration No. |
|
| February 15, 2023 |
Exhibit 21.1 GE HealthCare Technologies Inc. Subsidiaries of Registrant LEGAL ENTITY STATE OR COUNTRY OF INCORPORATION OR ORGANIZATION Beijing GE Hualun Medical Equipment Company Limited China BK Medical ApS Denmark BK Medical Australia Pty Ltd. Australia BK Medical Austria GmbH Austria BK Medical Benelux NV Belgium BK Medical France SAS France BK Medical Holding Company, Inc. Delaware BK Medical |
|
| February 15, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table S-8 (Form Type) GE HealthCare Technologies Inc. |
|
| February 15, 2023 |
Exhibit 10.11 GE HEALTHCARE TECHNOLOGIES INC. 2023 LONG-TERM INCENTIVE PLAN Section I.Purpose The purpose of this GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan is to attract, retain and motivate employees, officers, non-employee directors and other service providers of GE HealthCare Technologies Inc. (the “Company”). Stock- and performance-based compensation provided under this Pla |
|
| February 15, 2023 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, GE HealthCare Technologies Inc. ( “GE HealthCare,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exc |
|
| February 10, 2023 |
GEHC / GE Healthcare Holding LLC / GENERAL ELECTRIC CO - SCHEDULE 13G Passive Investment SC 13G 1 eh23032119713g-gehc.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GE HEALTHCARE TECHNOLOGIES INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 36266G 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) C |
|
| February 3, 2023 |
Exhibit 10.2 FORM OF AWARD FOR SECTION 16 OFFICERS [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Founders Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date February 1, 2023 |
|
| February 3, 2023 |
Exhibit 10.4 One GE HealthCare Annual Bonus Plan (effective January 1, 2023) I. Purpose The Plan is an annual performance-based bonus plan that incentivizes and rewards eligible employees of the Company for delivering on the Company’s financial, operating and strategic goals during a Plan Year. The Plan supersedes the terms of prior annual bonus plans, including the Annual Executive Incentive Plan |
|
| February 3, 2023 |
Exhibit 10.1 FORM OF AWARD FOR SECTION 16 OFFICERS OF COMPANY [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Founders Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date February 1, 2023 <> 50% February 1, 2025 50% February 1, 2026 |
|
| February 3, 2023 |
Exhibit 10.3 FORM OF AWARD FOR SECTION 16 OFFICERS Global Addendum Global Information for the GE HealthCare Technologies Inc. (“GE HealthCare” or “Company”) 2023 Long-Term Incentive Plan (the “Plan”) January 2023 This Addendum provides additional terms and conditions of your grant in Section A and specific additional information that applies to residents of the countries listed below in Section B. |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| January 30, 2023 |
GE HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results •4Q Revenues up 8% year-over-year, Organic revenues* up 13% •4Q Net income of $554 million versus $564 million for the prior year, Adjusted EBIT* of $844 million versus $827 million •4Q EPS were $1. |
|
| January 30, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co |
|
| January 10, 2023 |
Exhibit 99.1 GE HealthCare Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Results; Introduces 2023 Outlook Strong Revenue Growth Driven by Fulfillment and Demand CHICAGO, IL – January 10, 2023 – GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022. The Company also issue |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Com |
|
| January 4, 2023 |
EX-10.2 4 d386556dex102.htm EX-10.2 Exhibit 10.2 TAX MATTERS AGREEMENT by and between GENERAL ELECTRIC COMPANY and GE HEALTHCARE TECHNOLOGIES INC. Dated as of January 2, 2023 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS TAX MATTERS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT O |
|
| January 4, 2023 |
EX-10.1 Exhibit 10.1 TRANSITION SERVICES AGREEMENT BETWEEN GENERAL ELECTRIC COMPANY AND GE HEALTHCARE TECHNOLOGIES INC. DATED JANUARY 2, 2023 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS TRANSITION SERVICES AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTA |
|
| January 4, 2023 |
EX-2.1 Exhibit 2.1 SEPARATION AND DISTRIBUTION AGREEMENT by and between GENERAL ELECTRIC COMPANY and GE HEALTHCARE HOLDING LLC Dated as of November 7, 2022 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS SEPARATION AND DISTRIBUTION AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1 |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis |
|
| January 4, 2023 |
GE HealthCare Completes Spin-Off and Begins Trading on Nasdaq EX-99.1 Exhibit 99.1 GE HealthCare Completes Spin-Off and Begins Trading on Nasdaq • A leader in precision care, focused on creating a world where healthcare has no limits • Attractive financial profile supported by commitment to accelerating growth, margin expansion, and free cash flow generation through organic investment, business optimization, and disciplined capital allocation • Trading on Na |
|
| January 4, 2023 |
EX-10.4 Exhibit 10.4 TRADEMARK LICENSE AGREEMENT Name and Address of Licensee: GE HealthCare Imaging Holding Inc. 3000 N Grandview Blvd Waukesha, WI 53188 Attn: [***] E-mail: [***] with a copy (which will not constitute notice) to: GE HealthCare 500 West Monroe Street Chicago, IL 60661 Attn: [***] E-mail: [***] Name and Address of Parent: General Electric Company Trademark Operation 901 Main Ave N |
|
| January 4, 2023 |
EX-10.3 Exhibit 10.3 EMPLOYEE MATTERS AGREEMENT THIS EMPLOYEE MATTERS AGREEMENT (“Employee Matters Agreement”) is executed effective as of January 2, 2023, by and between General Electric Company, a New York corporation (“Parent”) and GE HealthCare Technologies Inc., a Delaware corporation (“SpinCo”) (collectively, the “Parties”). WHEREAS, the Parties have entered into a Separation and Distributio |
|
| January 4, 2023 |
EX-10.5 Exhibit 10.5 REAL ESTATE MATTERS AGREEMENT This REAL ESTATE MATTERS AGREEMENT (this “Agreement”) is entered into on January 2, 2023 by and between General Electric Company, a New York corporation (“Parent”), and GE HealthCare Technologies Inc., a Delaware corporation (“SpinCo”). R E C I T A L S: WHEREAS, in accordance with that certain Separation and Distribution Agreement dated as of Nove |
|
| January 4, 2023 |
EX-10.6 8 d386556dex106.htm EX-10.6 Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: |
|
| December 29, 2022 |
Consent of H. Lawrence Culp, Jr. as Director Nominee. Exhibit 99.1 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-8 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi |
